Attorney Docket No.: 6423.404-US PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Confirmation No.: 9325

Application No.: 10/602,838

Group Art Unit: 1654

Filing Date: June 24, 2003

Examiner: Ha, Julie

National Stage of PCT/DK02/00895

For: Liquid Composition of Factor VII Polypeptides

## FIRST SUPPLEMETAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby submit \_\_1\_ sheet listing references and other information for consideration by the Examiner in accordance with 37 C.F.R. 1.56, 1.97, and 1.98:

US Application No.: 10/602,838 Filing Date: June 24, 2003
Attorney Docket No.:6423.404-US Page 3 of 4

Except for US patent documents, a copy of each listed reference is enclosed or submitted

herewith. Copyrighted material submitted with this Information Disclosure Statement may be

delivered to the Government under license from the Copyright Clearance Center, Inc., or other

rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is

"prior art" unless it is specifically designated as such.

This information disclosure statement is being filed after the period set forth in 37 C.F.R.

1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action

that otherwise closes prosecution.

Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. §

1.17(p) (currently \$180.00). The Examiner is hereby authorized to charge Deposit Account No.

14-1447 in the amount of \$180.00. No further fees are due. However, please charge any fees

should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicants respectfully request that any references or other information listed above be

made of record in this patent application. The Examiner is invited to call the undersigned if there

are any questions concerning this submission or application.

Respectfully submitted,

Date: November 18, 2008

/Richard W. Bork, Reg. No. 36,459/

Richard W. Bork, Reg. No. 36,459 for Shelby J. Walker, Reg. No. 45,192

Novo Nordisk Inc.

Customer Number 23650

(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE